Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
February 21, 2020 08:00 ET
|
Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Arch...
Arch Biopartners Receives $332,750 From the Exercise of Warrants
June 26, 2018 09:03 ET
|
Arch Biopartners
TORONTO, June 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced that it received net...
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
March 09, 2018 08:00 ET
|
Arch Biopartners
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the...
Arch Biopartners Closes Convertible Note Financing
February 16, 2018 09:00 ET
|
Arch Biopartners
TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”)...
Arch Biopartners Arranges Convertible Note Financing
February 08, 2018 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial
December 06, 2017 10:08 ET
|
Arch Biopartners
TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production...